GSK, Novartis concede more ground in ACCC’s Voltaren case
Bird & Bird
2018-03-06 8:07 pm
| Melbourne
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
For information on rights and reprints, contact subscriptions@lawyerly.com.au